Mona Fiuzat, PharmD, FACC, FHFA, FHFSA is an Associate Professor of Medicine at Duke University, Senior Scientific Advisor at the FDA, Executive Editor of JACC: Heart Failure, and Former Senior Scientific Advisor to the FDA Commissioner. Her clinical research experience has been in clinical trials with a focus on pharmacogenetics in heart failure, and she helped file an NDA for the first proposed pharmacogenetically targeted heart failure drug. She worked in the Heart Failure Research Program at Duke on a number of key clinical trials as an investigator and steering committee member, and has authored or co-authored over 100 papers in the field of heart failure. Most recently, she helped develop and facilitate the “Heart Failure Collaboratory”, an effort of government agencies, academicians, patients, societies and payers to impact heart failure research and therapeutic development. She is a former Program Co-Chair for the Heart Failure Society of America’s (HFSA) Scientific Sessions, former Membership Co-Chair, and was recently elected to serve as HFSA Secretary. She serves on the HFSA Board of Directors and Executive Committee, HFSA Research Network Task Force, ACC Education and Outcomes Committee, AHA Nominations Committee, and FDA liaison to HFSA. She is the 2019 recipient of the ACC Distinguished Associate Award.